140 related articles for article (PubMed ID: 23110703)
1. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
[TBL] [Abstract][Full Text] [Related]
2. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
[TBL] [Abstract][Full Text] [Related]
6. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y; Mizutani C; Nannya Y; Kurokawa M; Kobayashi S; Takeuchi J; Tamura H; Ogata K; Dan K; Shibayama H; Kanakura Y; Niimi K; Sasaki K; Watanabe M; Emi N; Teramura M; Motoji T; Kida M; Usuki K; Takada S; Sakura T; Ito Y; Ohyashiki K; Ogawa H; Suzuki T; Ozawa K; Imai K; Kasai M; Hata T; Miyazaki Y; Morita Y; Kanamaru A; Matsuda A; Tohyama K; Koga D; Tamaki H; Mitani K; Naoe T; Sugiyama H; Takaku F
Leuk Lymphoma; 2013 Jul; 54(7):1450-8. PubMed ID: 23110324
[TBL] [Abstract][Full Text] [Related]
8. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
9. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
10. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
12. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
13. [Clinical implication of minimal residue disease monitoring by WT1 gene detection and flow cytometry in myelodysplastic syndrome with allogeneic stem cell transplantation].
Zhao XS; Mo XD; Hong Y; Chang YJ; Qin YZ; Liu YR; Chen YY; Zhang XH; Xu LP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):998-1003. PubMed ID: 30612401
[No Abstract] [Full Text] [Related]
14. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
15. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
16. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.
Yoon JH; Jeon YW; Yahng SA; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Kim HJ; Lee S; Min CK; Cho SG; Kim Y; Kim DW; Lee JW; Han K; Min WS; Park CW; Kim M; Kim YJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):460-7. PubMed ID: 25460359
[TBL] [Abstract][Full Text] [Related]
19. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome].
Cheng YF; Zhang LP; Liu YR; Qin YZ; Wu J; Liu GL
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):536-40. PubMed ID: 22967413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]